Back to search

Article

Subclonal evolution in the mutational landscape of early Triple negative breast cancer (TNBC) on multi-agent chemotherapy: Comparison of Pre- And Post-Neoadjuvant Chemotherapy (NAC) Samples Of TNBC Patients With Residual Disease

2022-10-31

Abstract excerpt

<h4>Background: </h4> Triple-negative breast cancer (TNBC) with residual disease post chemotherapy, have increased chance of relapse and lower survival with varying degree of pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). However, the risk of recurrence is high among those who do not achieve pCR and characterizing the mutational landscape of this fairly heterogeneous subset of patients...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
fd92eaf9-40ea-544c-b778-1b6d12f0b580
DOI
10.21203/rs.3.rs-2197673/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Subclonal evolution in the mutational landscape of early Triple negative breast cancer (TNBC) on multi-agent chemotherapy: Comparison of Pre- And Post-Neoadjuvant Chemotherapy (NAC) Samples Of TNBC Patients With Residual DiseaseDOI 10.21203/rs.3.rs-2197673/v1
Comparative analysis of mutational patterns in triple negative breast cancer before and after neoadjuvant chemotherapy in patients with residual disease.Semantic proximity
The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers.Semantic proximity
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesSemantic proximity
The clonal and mutational evolution spectrum of primary triple-negative breast cancers.Semantic proximity
Frequent Whole-Genome Duplication Events Drive the Genomic Evolution of Triple-Negative Breast Cancer During Neoadjuvant ChemotherapySemantic proximity
Comparison of the Mutation Profiles of Triple-Negative Breast Cancers and Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers at the T2N0-1M0 StageSemantic proximity
The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.Semantic proximity
Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - one clinic experience.Semantic proximity
The clonal architecture and tumour microenvironment of breast cancers are shaped by neoadjuvant chemotherapySemantic proximity
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity
Frequent Whole-Genome Duplication Events Drive the Genomic Evolution of Triple-Negative Breast Cancer During Neoadjuvant ChemotherapySemantic proximity
Whole exome sequencing for identification of specific gene mutations in an Indian cohort of triple- negative breast cancer patientsSemantic proximity
Select a neighboring publication to make it the new centre.